MedDRA preferred term

Tic: adverse event reports recording this term

5,322 reports to FDA record it, 2004–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

5,322
reports recording the term: 0% of all reports; 229
reports, 12 months to June 2026: 220 in the 12 months before; 61.1%
marked serious by the reporter: 57.4% across all reports; 0.7%
record death among outcomes, as reported: 9.1% across all reports

5,322 reports in FDA's adverse event database record the MedDRA term "Tic": 0% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

229 reports recorded it in the 12 months to June 2026, close to the 220 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 61.1% are marked serious, 0.7% include death among the outcomes and 14.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Vyvanse, Strattera and Abilify. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Vyvanse	Central nervous system stimulant	323	1.8%
Strattera	Norepinephrine reuptake inhibitor	302	1.9%
Abilify	Atypical antipsychotic	204	0.4%
Concerta	Central nervous system stimulant	190	1.8%
Singulair	Leukotriene receptor antagonist	188	1%
Risperdal	Atypical antipsychotic	180	0.3%
Montelukast	Leukotriene receptor antagonist	174	1.4%
Sertraline	Serotonin reuptake inhibitor	144	0.3%
Risperidone	Atypical antipsychotic	132	0.3%
MiraLAX	Osmotic laxative	127	0.3%
Daytrana	Central nervous system stimulant	109	0.8%
Seroquel	Atypical antipsychotic	104	0.2%
Fluoxetine	Serotonin reuptake inhibitor	88	0.3%
Aripiprazole	Atypical antipsychotic	84	0.3%
Lamotrigine	Anti-epileptic agent	71	0.2%
Adderall	Central nervous system stimulant	68	0.7%
Ingrezza	Vesicular monoamine transporter 2 inhibitor	64	0.3%
Latuda	Atypical antipsychotic	63	0.4%
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	59	0.1%
Montelukast sodium	Leukotriene receptor antagonist	54	0.8%
Methylphenidate	Central nervous system stimulant	53	0.8%
Methylphenidate hydrochloride	Central nervous system stimulant	51	0.9%
Xenazine	Vesicular monoamine transporter 2 inhibitor	51	0.8%
Quillivant	Central nervous system stimulant	48	2.4%
Ritalin	Central nervous system stimulant	47	0.8%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Atypical antipsychotic	1,036	0.2%	0.1%
Central nervous system stimulant	996	0.9%	0.3%
Leukotriene receptor antagonist	416	1.1%	1%
Serotonin reuptake inhibitor	416	0.2%	0.1%
Norepinephrine reuptake inhibitor	330	1.6%	0.6%
Anti-epileptic agent	174	0.1%	0%
Osmotic laxative	135	0.1%	0%
Vesicular monoamine transporter 2 inhibitor	124	0.4%	0.8%
Serotonin and norepinephrine reuptake inhibitor	96	0.1%	0%
Aminoketone	57	0.1%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.6%30

2 to 1125.7%1,366

12 to 1712.2%649

18 to 4414.7%783

45 to 649.2%487

65 to 742.6%137

75 and over2.1%110

Age not given33.1%1,760

Patient sex

Female36%1,918

Male53.5%2,845

Not given10.5%559

Grey bar: all 20,646,523 reports in the database. 62.4% of these reports give the United States as the country.

Questions about "Tic"

What does "Tic" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record tic?

5,322 reports through June 2026 (0% of all reports), 229 of them in the latest 12 months.

Which drugs appear most often in these reports?

Vyvanse (323), Strattera (302), Abilify (204), Concerta (190) and Singulair (188). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.